Chronic Myelomonocytic Leukaemia - Pipeline Insight, 2024

This “Chronic Myelomonocytic Leukaemia - Pipeline Insight, 2024” report provides comprehensive insights about 22+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Myelomonocytic Leukaemia: Understanding

Chronic Myelomonocytic Leukaemia: Overview

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (~15-20% over 3-5 years). CMML is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes,’ in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red blood cells, white blood cells, or platelets). MDS is a group of diseases that affect, to a greater or lesser extent, the production of normal blood cells in the bone marrow. Around 50% of people diagnosed have a type of CMML with a high white blood cell count and resemble people with MPN. The other 50% have a normal or reduced white blood cell count at diagnosis, and the disease is more similar to MDS. CMML is different from chronic myeloid leukaemia (CML). CML affects the myeloid cells in the blood and bone marrow, while CMML affects a specific myeloid cell called a monocyte, which helps fight infections. Potentially, any incident that damages the genetic material of the body can cause a mutation that may lead to the development of CMML. Examples of these incidents may include: ageing, cytotoxic chemotherapy, and radiation. CMML is not infectious and cannot be transmitted from one person to another. Many people are diagnosed after having a blood test for another problem. When abnormal monocytes are found, further tests are organized, including further blood tests, bone marrow biopsy or cytogenetic tests. CML affects the myeloid cells in the blood and bone marrow, while CMML affects a specific myeloid cell called a monocyte, which helps to fight infections.

" Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Myelomonocytic Leukaemia pipeline landscape is provided which includes the disease overview and Chronic Myelomonocytic Leukaemia treatment guidelines. The assessment part of the report embraces, in depth Chronic Myelomonocytic Leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Myelomonocytic Leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelomonocytic Leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

Chronic Myelomonocytic Leukaemia Emerging Drugs Chapters

This segment of the Chronic Myelomonocytic Leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Myelomonocytic Leukaemia Emerging Drugs

Sabatolimab : Novartis

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. Currently, the drug is in Phase III stage of development for the treatment of Chronic Myelomonocytic Leukaemia.

Ruxolitinib : Incyte Corporation

Ruxolitinib (Jakafi) is a first-in-class inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2. The result of this inhibition is disruption of cytokine and growth factor signaling pathways, leading to a decrease in proinflammatory cytokines and chemokines. In the clinical study, Ruxoltinib demonstrated meaningful clinical activity in CMML patients with splenomegaly and/or high disease symptom burden. The drug is already approved by the US Food and Drug Administration for the treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Jakafi is also indicated for the treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The drug is currently in Phase II stage of development for the treatment of Chronic Myelomonocytic Leukaemia.

NMS-03592088: Nerviano Medical Sciences

NMS-03592088 (NMS-088) is a potent inhibitor of FLT3, KIT, and CSF1R kinases. NMS-088 is the most active compound among the FLT3 comparators, a finding especially evident in the presence of the FLT3 “gatekeeper mutation,” which is associated with clinical resistance to treatment with other FLT3 inhibitors. There is a rationale for the use of the molecule in Chronic Myelomonocytic Leukemia (CMML) on the basis of the demonstrated inhibition of CSF1R, a highly expressed and activated target in this tumor type. The drug is currently in the Phase I/II stage of development for the treatment of CMML.

LP-108: Guangzhou Lupeng Pharmaceutical

LP-108 is a proto-oncogene protein (c-bcl-2) inhibitor. The drug is currently in Phase I stage of development for the treatment of CMML.

Chronic Myelomonocytic Leukaemia: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Myelomonocytic Leukaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diffuse Large B-Cell Lymphoma

There are approx. 22+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Chronic Myelomonocytic Leukaemia drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Myelomonocytic Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Myelomonocytic Leukaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Myelomonocytic Leukaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Myelomonocytic Leukaemia drugs.

Chronic Myelomonocytic Leukaemia Report Insights

• Chronic Myelomonocytic Leukaemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Myelomonocytic Leukaemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Myelomonocytic Leukaemia drugs?
• How many Chronic Myelomonocytic Leukaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Large B-Cell Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Myelomonocytic Leukaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Myelomonocytic Leukaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Humanigen
• Incyte Corporation
• Genetech
• Celgene
• AbbVie
• Amgen
• Nerviano Medical Sciences
• Guangzhou Lupeng Pharmaceutical

Key Products

• Lenzilumab
• Sabatolimab
• Ruxolitinib
• Venetoclax
• NMS-03592088
• LP-108
• AMG-176

This product will be delivered within 1-3 business days.